✨ Unlock Data Exports And Disclosure Access.Start Your 30-Day Free Trial Today →

Sichuan Biokin Pharmaceutical Co Ltd

Common Name
Sichuan Biokin Pharmaceutical
Country
China (Mainland)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
2,521
Ticker
688506
Exchange
SHANGHAI STOCK EXCHANGE
Description
Sichuan Biokin Pharmaceutical Co., Ltd. is a key player in the pharmaceutical industry, primarily focused on the research, development, production, and marketing of innovative drugs. The company speci...

Sichuan Biokin Pharmaceutical's GHG Emissions Data Preview

In 2025, Sichuan Biokin Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy) and Scope 3 (indirect emissions across the value chain).

Sichuan Biokin Pharmaceutical has also provided a category-level breakdown for 2 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.

Metric (tCO2e)20252024
Total Scope 1
8,090.43a
7,222.55a
Total Scope 2
Unspecified Calculation Method
14,138.86a
15,101.56a
Total Scope 3
613.24a
861.82a
Total Scope 1 Revenue Intensity (tCO2e/$M)
22.4751a
9.0526a
Usage Policy

You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"

Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.

Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=688506&reporting_period=2025"

Verified Sources Behind Sichuan Biokin Pharmaceutical’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.

a. Sichuan Biokin Pharmaceutical's ESG Report 2025
a. Sichuan Biokin Pharmaceutical's ESG Report 2025

Insights into Sichuan Biokin Pharmaceutical's Operational Emissions

In 2025, the total operational greenhouse gas (GHG) emissions of Sichuan Biokin Pharmaceutical amounted to 22,229.29 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Compared to 2024, the total operational greenhouse gas (GHG) emissions of Sichuan Biokin Pharmaceutical decreased by 0.42%, showing that the company has made progress in taking action to reduce the climate impact of its operations.a

Sichuan Biokin Pharmaceutical's Scope 1 Emissions Over Time

2024202502.5 k5 k7.5 k10 ktCO2e+12%
  • Total Scope 1
  • Year-over-Year Change

What are Sichuan Biokin Pharmaceutical's Scope 1 emissions?

In 2025, the total Scope 1 emissions of Sichuan Biokin Pharmaceutical were 8,090.43 metric tons of CO₂ equivalent (tCO₂e).a

Compared to the previous year (2024), Sichuan Biokin Pharmaceutical's Scope 1 emissions increased by 12.02%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.a

What are Sichuan Biokin Pharmaceutical's Scope 2 emissions?

In 2025, Sichuan Biokin Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 14,138.86 tCO₂e without specifying the calculation method.a

Has Sichuan Biokin Pharmaceutical reduced its Scope 2 emissions over time?

Compared to the previous year (2024), Sichuan Biokin Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Sichuan Biokin Pharmaceutical's emissions have plateaued with no significant change in its energy consumption footprint.a

What methodology does Sichuan Biokin Pharmaceutical use for Scope 2 reporting?

In 2025, Sichuan Biokin Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.a

Sichuan Biokin Pharmaceutical's Scope 2 Emissions Over Time

2024202504 k8 k12 k16 ktCO2e
  • Total Scope 2 (Unspecified Calculation Method)

Insights into Sichuan Biokin Pharmaceutical's Value Chain Emissions

In 2025, Sichuan Biokin Pharmaceutical reported 613.24 metric tons of CO₂ equivalent (tCO₂e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.a

The 2025 disclosure of Sichuan Biokin Pharmaceutical includes a breakdown across 2 of the 15 Scope 3 categories defined by the GHG Protocol, up from 0 in 2024, reflecting improved emissions accounting practices and greater transparency across the company's value chaina

Sichuan Biokin Pharmaceutical's Scope 3 Emissions Over Time

2024202502505007501 ktCO2e-29%
  • Total Scope 3
  • Year-over-Year Change

What are Sichuan Biokin Pharmaceutical's Scope 3 emissions?

In 2025, Sichuan Biokin Pharmaceutical reported total Scope 3 emissions of 613.24 metric tons of CO₂ equivalent (tCO₂e).a

Approximately 100% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0% came from downstream activities like product use, distribution, and end-of-life treatment.a

Compared to the previous year (2024), Sichuan Biokin Pharmaceutical's Scope 3 emissions decreased by 28.84%, highlighting the company's efforts to lower indirect emissions from its value chain.a

What categories of Scope 3 emissions does Sichuan Biokin Pharmaceutical disclose?

In 2025, Sichuan Biokin Pharmaceutical reported emissions for 2 out of the 15 Scope 3 categories defined by the GHG Protocol.a

The limited disclosure restricts visibility into specific emission sources across the company's value chain.

What are the main sources of Sichuan Biokin Pharmaceutical's Scope 3 emissions?

In 2025, the largest contributors to Sichuan Biokin Pharmaceutical's Scope 3 emissions were:a

  • Business Travel (Cat. 6): 342.18 tCO₂e (55.8%)
  • Waste Generated in Operations (Cat. 5): 271.06 tCO₂e (44.2%)

Sichuan Biokin Pharmaceutical's Scope 3 Emissions by Categories

Waste Generated inOperations (Cat. 5)(44.2%)Business Travel(Cat. 6)(55.8%)

Insights into Sichuan Biokin Pharmaceutical’s GHG Emissions Intensity Compared to Industry Peers

In 2025, Sichuan Biokin Pharmaceutical reported Scope 1 greenhouse gas (GHG) emissions of 8,090.43 tCO₂e and total revenues of USD 360 millions. This translates into an emissions intensity of 22.48 tCO₂e per millions USD.a

Sichuan Biokin Pharmaceutical's Scope 1 Emissions Intensity Compared to Peers

2002,00020,000200,0005,000,000Scope 1 Emissions (tCO2e)502001,0002,00010,000Revenues (Millions of USD)Apeloa PharmaceuticalYear: 2025Scope 1: 75,760 tCO2eRevenue: $M 1,397Scope 1 Intensity: 54.21 tCO2e/$MZhejiang Huahai PharmaceuticalYear: 2024Scope 1: 58,691 tCO2eRevenue: $M 1,308Scope 1 Intensity: 44.86 tCO2e/$MLivzon Pharmaceutical GroupYear: 2025Scope 1: 175,562 tCO2eRevenue: $M 1,717Scope 1 Intensity: 102.25 tCO2e/$MDizal PharmaceuticalYear: 2025Scope 1: 887 tCO2eRevenue: $M 114Scope 1 Intensity: 7.75 tCO2e/$MChangchun High-TechYear: 2025Scope 1: 133,335 tCO2eRevenue: $M 1,726Scope 1 Intensity: 77.25 tCO2e/$MSimcere Pharmaceutical GroupYear: 2025Scope 1: 5,428 tCO2eRevenue: $M 1,104Scope 1 Intensity: 4.92 tCO2e/$MHumanwell Healthcare (Group)Year: 2025Scope 1: 24,083 tCO2eRevenue: $M 3,423Scope 1 Intensity: 7.04 tCO2e/$MDa Ren TangYear: 2025Scope 1: 3,870 tCO2eRevenue: $M 702Scope 1 Intensity: 5.51 tCO2e/$MDong-E-E-JiaoYear: 2024Scope 1: 20,046 tCO2eRevenue: $M 811Scope 1 Intensity: 24.71 tCO2e/$MBeijing Tong Ren TangYear: 2025Scope 1: 28,656 tCO2eRevenue: $M 2,465Scope 1 Intensity: 11.63 tCO2e/$MShenzhen Salubris PharmaceuticalsYear: 2024Scope 1: 11,399 tCO2eRevenue: $M 550Scope 1 Intensity: 20.73 tCO2e/$MChina Resources SanjiuYear: 2025Scope 1: 61,350 tCO2eRevenue: $M 4,514Scope 1 Intensity: 13.59 tCO2e/$MHansoh Pharmaceutical GroupYear: 2025Scope 1: 11,834 tCO2eRevenue: $M 2,147Scope 1 Intensity: 5.51 tCO2e/$MJiangsu Hengrui PharmaceuticalsYear: 2025Scope 1: 54,874 tCO2eRevenue: $M 4,518Scope 1 Intensity: 12.15 tCO2e/$MHuadong MedicineYear: 2025Scope 1: 18,686 tCO2eRevenue: $M 6,230Scope 1 Intensity: 3.00 tCO2e/$MFosun PharmaYear: 2025Scope 1: 230,379 tCO2eRevenue: $M 5,951Scope 1 Intensity: 38.71 tCO2e/$MZhejiang NhuYear: 2025Scope 1: 897,516 tCO2eRevenue: $M 3,178Scope 1 Intensity: 282.38 tCO2e/$MYunnan Baiyao GroupYear: 2025Scope 1: 34,719 tCO2eRevenue: $M 5,883Scope 1 Intensity: 5.90 tCO2e/$MPorton Pharma SolutionsYear: 2025Scope 1: 9,489 tCO2eRevenue: $M 488Scope 1 Intensity: 19.43 tCO2e/$MSihuan PharmaceuticalYear: 2023Scope 1: 45,602 tCO2eRevenue: $M 262Scope 1 Intensity: 174.19 tCO2e/$MConsun Pharmaceutical GroupYear: 2025Scope 1: 7,133 tCO2eRevenue: $M 488Scope 1 Intensity: 14.61 tCO2e/$MBioKangtaiYear: 2025Scope 1: 15,001 tCO2eRevenue: $M 382Scope 1 Intensity: 39.29 tCO2e/$MBetta PharmaceuticalsYear: 2025Scope 1: 1,268 tCO2eRevenue: $M 516Scope 1 Intensity: 2.46 tCO2e/$MWalvax BiotechnologyYear: 2024Scope 1: 7,643 tCO2eRevenue: $M 387Scope 1 Intensity: 19.77 tCO2e/$MSichuan Biokin PharmaceuticalYear: 2025Scope 1: 8,090 tCO2eRevenue: $M 360Scope 1 Intensity: 22.48 tCO2e/$M

How does Sichuan Biokin Pharmaceutical's GHG emissions intensity compare to its peers?

In 2025, Sichuan Biokin Pharmaceutical reported a Scope 1 emissions intensity of 22.48 tCO₂e per millions USD. Compared to the peer group median of 17.02, this places the company above its industry benchmark, indicating it is less carbon-efficient than most competitors.a

Where does Sichuan Biokin Pharmaceutical rank on GHG emissions intensity within its industry?

In 2025, Sichuan Biokin Pharmaceutical ranked 16 out of 24 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

Sichuan Biokin Pharmaceutical is therefore positioned in the mid-range of its industry, neither a clear leader nor a laggard in carbon efficiency.a

Insights into Sichuan Biokin Pharmaceutical's Total Carbon Footprint

In 2025, Sichuan Biokin Pharmaceutical reported a total carbon footprint of 22,842.53 metric tons of CO₂ equivalent (tCO₂e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 1.48% decrease compared to 2024, indicating progress in reducing its overall greenhouse gas output.a

The largest contributor to Sichuan Biokin Pharmaceutical's total carbon footprint was Scope 2 emissions, accounting for 61.9% of the company's total carbon footprint, followed by Scope 1 emissions at 35.42%.a

Want Full Access to Sichuan Biokin Pharmaceutical's GHG Emissions Dataset?
Start 30-Day Free Trial